N. Nora Bennani

Aug 11, 2024 | nature.com | Razan Mohty |Radhika Bansal |Urshila Durani |Madiha Iqbal |Yucai Wang |Jonas Paludo | +8 more

Dear Editor,Hemophagocytic lymphohistiocytosis (HLH) is a rare complication of chimeric antigen receptor T-cell (CAR-T) therapy [1,2,3]. With the increasing use of CAR-T therapy in treating hematological malignancies, the unique phenomenon of CAR-T-associated HLH (carHLH) is increasingly recognized. Albeit rare, reported rates vary from 1–3% to 35% depending on the underlying disease, patient population and the CAR-T product [1,2,3].

Apr 2, 2024 | cgtlive.com | N. Nora Bennani

“The idea is to find targets that will not eliminate all T-cells, and rather, maybe find a target that may eliminate part of the T-cells, but not all, so the patients are still having good immune function to some degree.

Feb 19, 2024 | cgtlive.com | N. Nora Bennani

“Currently, we've added a few arms where we are trying to prime the immune system for the patients to have a better immune response post VSV therapy. So, we are giving a one-time infusion of checkpoint blockers, pre VSV therapy, and that arm just recently opened, and it is currently enrolling. So very exciting things for our patients.

Aug 17, 2023 | nature.com | William Breen |Jason Young |Radhika Bansal |N. Nora Bennani |Jonas Paludo |Yucai Wang | +2 more

AbstractPET/CT is used to evaluate relapsed/refractory non-Hodgkin lymphoma (NHL) prior to chimeric antigen receptor T-cell (CAR-T) infusion at two time points: pre-leukapheresis (pre-leuk) and pre-lymphodepletion chemotherapy (pre-LD). We hypothesized that changes in PET/CT between these time points predict outcomes after CAR-T.